VistaGen Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US92840H4002 (VTGN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). Read full profile
Stock price
Fundamentals
- Net revenue
€554.27K - Gross margin
48.9% - EBIT
-€51.18M - EBIT margin
-9,233.1% - Net income
-€47.86M - Net margin
-8,634.7%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: August 8, 2025
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |